COMPANY PROFILE / #1246
ClearNote Health
San Diego, CAVenture Capital-Backed
OVERVIEW
Developer of a proprietary epigenomic technology designed to detect high-mortality cancers at an early, more treatable stage through a standard blood draw. The company's technology offers non-invasive, cell-free DNA-based assays that track dynamic biological changes using biomarkers and artificial intelligence, enabling high-risk individuals, such as those with newly diagnosed type 2 diabetes or predisposition to pancreatic and ovarian cancers, to access early detection and improved treatment outcomes.
已融资180.05
最新估值274.50
员工数49
成立年份2016
公司概况
- Companies
- ClearNote Health
- Description
- Developer of a proprietary epigenomic technology designed to detect high-mortality cancers at an early, more treatable stage through a standard blood draw. The company's technology offers non-invasive, cell-free DNA-based assays that track dynamic biological changes using biomarkers and artificial intelligence, enabling high-risk individuals, such as those with newly diagnosed type 2 diabetes or predisposition to pancreatic and ovarian cancers, to access early detection and improved treatment outcomes.
- Website
- www.clearnotehealth.com
- HQ Location
- San Diego, CA
- Year Founded
- 2016
- Keywords
- biopsy test, biotechnology research, cancer detection platform, cancer detection service, cancer diagnostics, clinical diagnostics test, liquid biopsy diagnostics
- Competitors
- —
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 180.05
- First Financing Date
- —
- First Financing Size
- 5.00
- First Financing Valuation
- 16.50
- Last Financing Date
- 27-May-2026
- Last Financing Deal Type
- Later Stage VC
- Last Financing Size
- 52.00
- Last Financing Valuation
- 274.50
- Last Financing Status
- Completed
- Last Known Valuation
- 274.50
- Last Known Valuation Date
- 27-May-2026
- Last Known Valuation Deal Type
- Later Stage VC
- Valuation Estimate
- 296.56
- Valuation Estimate Growth Rate
- 8.04%
- Active Investors
- Mattias Westman, Pathology Asia Holdings, Prosperity Capital Management, Sanford Weill
- # Active Investors
- 4
- Acquirers
- —
团队与联系人
- Employees
- 49
- Employee Growth %
- 11.36%
- Employee History
- 2026: 49, 2025: 44, 2024: 33, 2023: 32, 2022: 42, 2021: 30, 2020: 23 E, 2019: 16
- Primary Contact
- Samuel Levy
- Primary Contact Title
- Chief Scientific Officer
- Primary Contact Email
- slevy@clearnotehealth.com
- Primary Contact Phone
- +1 (833) 258-7827
增长与经营
- Revenue
- 6.00
- Revenue Growth %
- —
- Growth Rate
- 0.13%
- Growth Rate % Change
- —
- Growth Rate Percentile
- 90
- Size Multiple
- 3.88x
- Size Multiple % Change
- 0.00%
- Size Multiple Change
- 0.00x
- Size Multiple Percentile
- 78
- Majestic Referring Domains
- 101
- SimilarWeb Unique Visitors
- 990
- SimilarWeb Unique Visitors Change
- 92
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 29%
- Success Probability Over Time – 3 Year
- 46%
- Success Probability Over Time – 5 Year
- 58%
记录来源：public.companies · 原始序号 #1246 · 所有字段均按数据库原值展示。